TIRC7 and HLA-DR axis contributes to inflammation in multiple sclerosis.

Area of Science:

• Immunology
• Neuroscience
• Cell Biology

Background:

• The seven-transmembrane receptor TIRC7 (T-cell immune response gene 10) and its ligand HLA-DR may play a role in the inflammatory processes of multiple sclerosis (MS).
• Understanding the molecular interactions in MS pathogenesis is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the role of TIRC7 and its interaction with HLA-DR in the inflammatory context of multiple sclerosis.
• To evaluate the potential of targeting the TIRC7-HLA-DR pathway as a therapeutic strategy for MS.

Main Methods:

• Immunohistochemistry and microscopy on archival MS autopsies.
• Proliferation, cytokine, and surface-staining assays on peripheral blood lymphocytes (PBLs) from MS patients and an in vitro model.
• Utilized an anti-TIRC7 monoclonal antibody (mAb) to block TIRC7-HLA-DR interactions.

Main Results:

• TIRC7 expression was detected in brain-infiltrating lymphocytes and correlated with MS disease activity.
• TIRC7 expression patterns differed between T cells and B cells in MS patients' PBLs, with restoration upon activation in active MS.
• Blocking TIRC7-HLA-DR interaction with anti-TIRC7 mAb inhibited T cell proliferation and Th1/Th17 cytokine production in MS patient-derived cells and T cell clones.

Conclusions:

• TIRC7 is involved in MS-related inflammation, mediating T cell activation and cytokine production.
• Anti-TIRC7 mAb demonstrates potential as a therapeutic agent by selectively inhibiting key inflammatory pathways in MS.
• Targeting the TIRC7 pathway represents a promising novel treatment strategy for multiple sclerosis.